

A facile synthesis of 2,5-dihydroisoxazoles via an organoselenium-induced stereoselective cyclisation and deselenylation reaction

Xian Huang^{a,b*} and E Tang^a

^aDepartment of Chemistry, Zhejiang University (Xixi Campus), Hangzhou 310028, P. R. China


^bState key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, P. R. China

The organoselenium-induced ring-closure reactions of *O*-allyl oximes give cyclic iminium salts that can be reduced *in situ* with NaBH₄ to produce *N*-alkyl-4-phenylselenoisoxazolidines; selenoxide *syn*-elimination follows to form 2,5-dihydroisoxazoles in good yields.

Keywords: *O*-allyl oximes, 2,5-dihydroisoxazoles, organoselenium-induced, cyclisation, deselenylation reaction

Isxazolines are important synthetic intermediates for functionalised building blocks.¹ A number of pharmaceutically active agents contain an optical isoxazoline ring, which plays an important role in their biological activities.^{2,3} Reports concerning the syntheses of 2,5-dihydroisoxazoles included the modification of cyclic compounds⁴⁻⁷ and intercyclisation of two substrates.^{8,9} However, to the best of our knowledge, the synthesis of 2,5-dihydroisoxazoles via intracyclisation has not been reported. Herein, we report a facile and efficient synthesis of 2,5-dihydroisoxazoles via an electrophilic selenium-induced intracyclisation and deselenenylation reaction of *O*-allyl oximes.

Firstly, **1a** was treated with phenylselenenyl bromide to produce 4-phenylselenenyl iminium bromide **2a**, which was not isolated from the solvent due to its instability. Then **2a** underwent reduction by NaBH₄ to afford the corresponding 2-alkyl-4-phenylselenenyl isoxazolidine **3a** in 80% yield. The isoxazolidine **3a** was then treated with hydrogen peroxide (30%) at 0°C to give product **4a** in 66% overall yield (Scheme 1).



Scheme 1

As indicated in Scheme 1, the reaction proceeded through the initial formation of the seleniranium ion intermediate and the cyclic iminium bromide **2a**.¹⁰ Compound **3a** was in fact obtained as a single *trans* stereoisomer which was confirmed by its ¹H NMR spectrum. The observed coupling (*J*_{3,4}) of 5.6 Hz for **3a** (Table 1, entry 1) was in agreement with the reported values for *J*_{3,4} of *trans*-3-substituted-4-phenylselenoisoxazolidines¹⁰ and *trans*-3,4-substituted isoxazolidines.¹¹

In order to extend this result, various *O*-allyl oximes were chosen as substrates and *N*-alkyl-2,5-dihydroisoxazoles were obtained in moderate to good yields. The results are summarised in Table 1.

In conclusion, a simple and facile method for the synthesis of 2,5-dihydroisoxazoles by oxidation-*syn*-selenoxide elimination of *N*-alkyl-4-phenylselenoisoxazolidines, which were prepared by organoselenium-induced stereoselective intracyclisation of *O*-allyl oximes, has been developed with the advantages of

Table 1 Preparation of 2,5-dihydroisoxazoles

Entry	R ¹	R ²	Product 4a (Yield%) ^b
1	<i>p</i> -CH ₃ C ₆ H ₄	H	4a (66)
2	C ₆ H ₅	H	4b (61)
3	<i>p</i> -ClC ₆ H ₄	H	4c (65)
4	<i>p</i> -BrC ₆ H ₄	H	4d (62)
5	<i>p</i> -CH ₃ OC ₆ H ₄	H	4e (73)
6	C ₂ H ₅	C ₂ H ₅	4f (65)
7	C ₆ H ₅	CH ₃	4g (62)
8	(CH ₂) ₅		4h (67)

^aAll products were identified by ¹H NMR, IR, MS and elemental analysis; ^bIsolated total yield.

available starting material, a simple procedure, mild reaction conditions and good yields.

Experimental

¹H NMR (400 MHz) was recorded on a Bruker Avance (400 MHz) spectrometer using CDCl₃ as the solvent and TMS as the internal standard. Mass spectra (EI, 70 eV) were recorded on a HP5989B mass spectrometer. Infrared spectra were recorded on a Bruker Vector22 infrared spectrometer. Elemental analyses were performed on a Flash EA1112 instrument. Dichloromethane was dried with calcium hydride and THF was distilled from sodium/benzophenone immediately prior to use.

Typical procedure for the synthesis of 2-(4-methylbenzyl)-3-phenyl-4-phenylselenoisoxazolidine (3a**):** To a solution of *O*-allyl oxime **1a** (1 mmol) in dry dichloromethane (3 ml) was added dropwise the solution of phenylselenenyl bromide (1.1 mmol) in dry dichloromethane (2 ml) at room temperature and the mixture was stirred for 1.5 h. Then, NaBH₄ (1.5 mmol) in methanol (1 ml) was added and the solution was stirred at room temperature for 1 h. The reaction mixture was poured into water (15 ml) and extracted with dichloromethane (10 ml × 3). The organic extracts were combined and dried over MgSO₄. After evaporating solvent, the oily residue was subjected to preparative TLC on silica gel with ethyl acetate and light petroleum (1:9) as eluent to give 327 mg of 2-(4-methylbenzyl)-3-phenyl-4-phenylselenoisoxazolidine **3a** (80%). oil; ¹H NMR (400 MHz, CDCl₃) δ 7.45–7.16 (m, 12H); 7.09 (d, 2H, *J* = 7.6 Hz); 4.47 (dd, 1H, *J* = 8.0 and 8.8 Hz); 4.09 (dd, 1H, *J* = 5.6 and 8.8 Hz); 3.93 (d, 1H, *J* = 14.0 Hz); 3.87 (dt, 1H, *J* = 5.6, 8.0 Hz); 3.74 (d, 1H, *J* = 5.6 Hz); 3.71 (d, 1H, *J* = 14.0 Hz); 2.31 (s, 3H); MS (*m/e*) 410–407 (M⁺), 316, 271, 252, 225, 210, 146, 117, 105 (100), 91, 77; IR (neat) 3060, 2923, 2852, 1601, 1578, 1514, 1438, 1377, 1021, 807, 766, 734, 691 cm⁻¹. Anal. calcd. for C₂₃H₂₃NOSe: C, 67.64; H, 5.68; N, 3.43. Found: C, 67.85; H, 5.64; N, 3.48.

Typical Procedure for the synthesis of 2-(4-methylbenzyl)-3-phenyl-2,5-dihydroisoxazole (4a**):** To a solution of the isoxazolidine **3a** (0.5 mmol) in THF (5 ml) was added 30% hydrogen peroxide (3.5 mmol)

* Correspondence. E-mail: huangx@mail.hz.zj.cn

in 30 min at 0°C. The solution was warmed to room temperature and stirred for another 30 min. The reaction mixtures were washed with brine (15 ml) and extracted with dichloromethane (10 ml × 3). The organic extracts were combined and dried over MgSO₄. After evaporating the solvent, the oily residue was subjected to preparative TLC on silica gel with ethyl acetate and light petroleum (1:9) to afford 82.8 mg of **4a** (66% overall yield). oil; ¹H NMR (400 MHz, CDCl₃) δ 7.62–7.15 (m, 10H); 4.68 (s, 2H); 4.18 (s, 2H); 2.38 (s, 3H); MS (*m/e*) 251 (M⁺), 146, 117, 105 (100), 91, 77; IR (neat) 3060, 2923, 2852, 1674, 1578, 1438, 1021, 766, 734, 691 cm⁻¹. Anal. calcd for C₁₇H₁₇NO: C, 81.24; H, 6.82; N, 5.57. Found: C, 81.52; H, 6.87; N, 5.50.

2-Benzyl-3-phenyl-2,5-dihydroisoxazole (4b): oil; ¹H NMR (400 MHz, CDCl₃) δ 7.60–7.12 (m, 11H); 4.72 (s, 2H); 4.21 (s, 2H); MS (*m/e*) 237 (M⁺), 117, 91 (100), 77, 65, 51; IR (neat) 3059, 3029, 2926, 2850, 1672, 1577, 1547, 1493, 1475, 1438, 1069, 1021, 735, 694 cm⁻¹; Anal. calcd for C₁₆H₁₅NO: C, 80.98; H, 6.37; N, 5.90. Found: C, 80.71; H, 6.34; N, 5.86.

2-(4-Chlorobenzyl)-3-phenyl-2,5-dihydroisoxazole (4c): oil; ¹H NMR (400 MHz, CDCl₃) δ 7.37–7.16 (m, 10H); 4.70 (s, 2H); 4.16 (s, 2H); MS (*m/e*) 272 (M⁺), 146, 127, 125 (100), 117, 105, 91, 77; IR (neat) 3059, 2926, 2848, 1675, 1578, 1485, 1445, 1069, 1016, 797, 763, 737, 693 cm⁻¹. Anal. calcd for C₁₆H₁₄ClNO: C, 70.72; H, 5.19; N, 5.15. Found: C, 70.98; H, 5.25; N, 5.10.

2-(4-Bromobenzyl)-3-phenyl-2,5-dihydroisoxazole (4d): oil; ¹H NMR (400 MHz, CDCl₃) δ 7.55–7.20 (m, 10H); 4.71 (s, 2H); 4.15 (s, 2H); MS (*m/e*) 316 (M⁺), 171, 169, 146, 117 (100), 105, 91, 90, 77; IR (neat) 3057, 2925, 2849, 1673, 1580, 1484, 1441, 1069, 1014, 797, 764, 736, 693 cm⁻¹. Anal. calcd for C₁₆H₁₄BrNO: C, 60.78; H, 4.46; N, 4.43. Found: C, 60.55; H, 4.41; N, 4.48.

2-(4-Methoxybenzyl)-3-phenyl-2,5-dihydroisoxazole (4e): oil; ¹H NMR (400 MHz, CDCl₃) δ 7.60–7.01 (m, 10H); 4.62 (s, 2H); 4.14 (s, 2H); 3.87 (s, 3H); MS (*m/e*) 267 (M⁺), 121, 117 (100), 105, 91, 77; IR (neat) 3062, 2924, 2866, 1677, 1579, 1495, 1455, 1267, 1023, 736, 691 cm⁻¹. Anal. calcd for C₁₇H₁₇NO₂: C, 76.38; H, 6.41; N, 5.24. Found: C, 76.62; H, 6.37; N, 5.29.

2-(1-Ethyl-propyl)-3-phenyl-2,5-dihydroisoxazole (4f): oil; ¹H NMR (400 MHz, CDCl₃) δ 7.52–7.15 (m, 6H); 4.76 (d, 1H, *J* = 8.8 Hz); 4.67 (d, 1H, *J* = 8.8 Hz); 2.52 (m, 1H), 1.71–1.35 (m, 4H), 0.85 (t, 6H, *J* = 7.6 Hz); MS (*m/e*) 217 (M⁺) 202, 188, 117 (100), 91, 77; IR (neat) 3058, 2932, 2871, 1669, 1576, 1492, 1476, 1454, 1433, 1377, 1066, 1021, 739, 693 cm⁻¹. Anal. calcd for C₁₄H₁₉NO: C, 77.38; H, 8.81; N, 6.45. Found: C, 77.68; H, 8.85; N, 6.38.

2-(1-Phenylethyl)-3-phenyl-2,5-dihydroisoxazole (4g): oil; ¹H NMR (400 MHz, CDCl₃) δ 7.55–6.96 (m, 11H), 4.71 (d, 1H, *J* = 8.8 Hz); 4.58 (d, 1H, *J* = 8.8 Hz); 4.29 (q, 1H, *J* = 6.8 Hz); 1.63 (d, 3H, *J* = 6.8 Hz); MS (*m/e*) 251 (M⁺), 174, 146, 105 (100), 91, 77; IR (neat) 3060, 3028, 2930, 1675, 1597, 1577, 1492, 1475, 1452, 1372, 1070, 1021, 909, 740, 697 cm⁻¹; Anal. calcd for C₁₇H₁₇NO: C, 81.24; H, 6.82; N, 5.57. Found: C, 81.60; H, 6.78; N, 5.61.

2-Cyclohexyl-3-phenyl-2,5-dihydroisoxazole (4h): oil; ¹H NMR (400 MHz, CDCl₃) δ 7.51–7.13 (m, 6H); 4.75 (d, 1H, *J* = 8.8 Hz); 4.67 (d, 1H, *J* = 8.8 Hz); 2.60 (m, 1H), 2.14–1.12 (m, 10H); MS (*m/e*) 229 (M⁺), 201, 186, 117 (100), 91, 77; IR (neat) 3060, 2932, 1668, 1577, 1493, 1475, 1434, 1068, 1022, 738, 693 cm⁻¹. Anal. calcd for C₁₅H₁₉NO: C, 78.56; H, 8.35; N, 6.11. Found: C, 78.31; H, 8.38; N, 6.17.

We thank the National Natural Science Foundation of China (No. 29932020) for financial support.

Received 15 October 2003; accepted 28 November 2003
Paper 03/2167

References

- 1 A.P. Kozikowski, *Acc. Chem. Res.*, 1984, **17**, 410.
- 2 J. Wityak, T.M. Sielecki, D.J. Pinto, G. Emmett, J.Y. Sze, J. Liu, A.E. Tobin, S. Wang, B. Jiang, P. Ma, S.A. Mousa, R.E. Olson and R.R. Wexler, *J. Med. Chem.*, 1997, **40**, 50.
- 3 W.C. Groutas, R. Venkataraman, L.S. Chong, J.E. Yoder, J.B. Epp, M.A. Stanga and E.H. Kim, *Bioorg. Med. Chem.*, 1995, **3**, 125.
- 4 S. Shatzmiller, E. Shalom, R. Lidor and E. Tartkovski, *Liebigs Ann. Chem.*, 1983, 906.
- 5 B. Alain and P. Clement, *Bull. Soc. Chim. Fr.*, 1974, (**5-6**), 1025.
- 6 A. Ikuo, R. Miyazaki and K. Hideo, *Chem. Pharm. Bull.*, 1974, **22**, 70.
- 7 A. Ikuo and K. Hideo, *Chem. Pharm. Bull.*, 1969, **17**, 2201.
- 8 L. Jurd, *Tetrahedron*, 1975, **31**, 2884.
- 9 H. Swidl, R. Huisgen and R. Knorr, *Chem. Ber.*, 1969, **102**, 904.
- 10 M. Tiecco, L. Testaferri, M. Tingoli, L. Bagnoli and F. Marini, *J. Chem. Soc. Chem. Commun.*, 1995, 235.
- 11 T. Yakura, M. Nakazawa, T. Takino and N. Ikeda, *Chem. Pharm. Bull.*, 1992, **40**, 2014.